Health Care & Life Sciences » Healthcare Provision | Shin Nippon Biomedical Laboratories Ltd.

Shin Nippon Biomedical Laboratories Ltd. | Cash Flow

Fiscal year is April-March. All values JPY Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
95,504.00
398,530.00
3,550,324.00
764,692.00
1,507,993.00
1,651
Depreciation, Depletion & Amortization
1,318,381.00
1,391,909.00
1,592,104.00
1,545,798.00
1,472,814.00
1,362
Other Funds
-
-
-
-
116.00
1,254
Funds from Operations
820,978.00
420,274.00
3,586,234.00
2,001,426.00
111,613.00
1,758
Changes in Working Capital
799,155.00
1,735,770.00
246,304.00
1,151,619.00
1,232,641.00
1,134
Net Operating Cash Flow
1,620,133.00
2,156,044.00
3,339,930.00
849,807.00
1,344,254.00
2,893
Capital Expenditures
1,745,681.00
1,468,739.00
1,808,179.00
1,015,871.00
1,018,251.00
Sale of Fixed Assets & Businesses
6,167.00
512,586.00
4,026,561.00
229,306.00
1,817,653.00
Purchase/Sale of Investments
15,152.00
134,514.00
2,475.00
507,949.00
678.00
Net Investing Cash Flow
1,772,582.00
1,092,783.00
1,285,985.00
314,206.00
837,824.00
Cash Dividends Paid - Total
1,196.00
31.00
-
-
-
Issuance/Reduction of Debt, Net
1,155,823.00
490,928.00
282,229.00
485,190.00
3,916,661.00
Net Financing Cash Flow
6,138,656.00
506,667.00
282,229.00
3,815,122.00
4,224,327.00
Net Change in Cash
3,118,557.00
2,476,216.00
2,326,832.00
2,498,168.00
2,129,710.00
Free Cash Flow
3,248,418.00
3,564,301.00
5,120,348.00
1,639,465.00
331,373.00
Net Assets from Acquisitions
-
-
-
30,963.00
-
Other Sources
111,288.00
5,200.00
71,712.00
44,378.00
48,285.00
Change in Capital Stock
7,295,675.00
15,770.00
-
3,329,932.00
16,574.00
Exchange Rate Effect
372,616.00
265,944.00
9,342.00
152,941.00
87,461.00
Other Uses
159,508.00
7,316.00
1,006,584.00
49,006.00
10,542.00

About Shin Nippon Biomedical Laboratories

View Profile
Address
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.snbl.co.jp
Updated 07/08/2019
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.